Hepatitis viruses

Section Editor: Alan McLachlan, University of Illinois at Chicago, USA 
Deputy Section Editor: Susan Uprichard, University of Illinois at Chicago, USA 

Previous Page Page 1 of 6 Next Page
  1. Research

    The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model

    Hydrodynamic injection (HI) of hepatitis B virus (HBV) mouse model is an useful tool for HBV related research in vivo. However, only 40% of C57/BL6 mice injected with 10 μg HBV genome contained plasmid (pAAV-H...

    Lei Li, Sheng Li, Yun Zhou, Lu Yang, Di Zhou, Yan Yang, Mengji Lu, Dongliang Yang and Jingjiao Song

    Virology Journal 2017 14:205

    Published on: 25 October 2017

  2. Research

    Chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants

    The pathogenesis of acute-on-chronic liver failure (ACLF) in chronic hepatitis B (CHB) is not well understood. The aim of this study was to investigate whether there is an association between HBV polymerase (P...

    Shan Gao, Shivali S. Joshi, Carla Osiowy, Y. Chen, Carla S. Coffin and Z-P. Duan

    Virology Journal 2017 14:203

    Published on: 24 October 2017

  3. Research

    Genetic polymorphisms of HLA-DP and isolated anti-HBc are important subsets of occult hepatitis B infection in Indonesian blood donors: a case-control study

    Occult hepatitis B infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the serum and/or liver in HBsAg-negative individuals. OBI is associated with the risk of viral transmission, espe...

    Yan Mardian, Yoshihiko Yano, Widya Wasityastuti, Neneng Ratnasari, Yujiao Liang, Wahyu Aristyaning Putri, Teguh Triyono and Yoshitake Hayashi

    Virology Journal 2017 14:201

    Published on: 23 October 2017

  4. Research

    Fucoidan from Fucus vesiculosus suppresses hepatitis B virus replication by enhancing extracellular signal-regulated Kinase activation

    Hepatitis B virus (HBV) infection is a serious public health problem leading to cirrhosis and hepatocellular carcinoma. As the clinical utility of current therapies is limited, the development of new therapeut...

    Huifang Li, Junru Li, Yuan Tang, Lin Lin, Zhanglian Xie, Jia Zhou, Liyun Zhang, Xiaoyong Zhang, Xiaoshan Zhao, Zhengliang Chen and Daming Zuo

    Virology Journal 2017 14:178

    Published on: 16 September 2017

  5. Review

    Hepatitis delta: virological and clinical aspects

    There are an estimated 400 million chronic carriers of HBV worldwide; between 15 and 20 million have serological evidence of exposure to HDV. Traditionally, regions with high rates of endemicity are central an...

    Luan Felipo Botelho-Souza, Mariana Pinheiro Alves Vasconcelos, Alcione de Oliveira dos Santos, Juan Miguel Villalobos Salcedo and Deusilene Souza Vieira

    Virology Journal 2017 14:177

    Published on: 13 September 2017

  6. Research

    Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C

    Direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the...

    Jung Hwan Yu, Jung Il Lee, Kwan Sik Lee and Ja Kyung Kim

    Virology Journal 2017 14:164

    Published on: 24 August 2017

  7. Research

    Prevalence of hepatitis-C virus genotypes and potential transmission risks in Malakand Khyber Pakhtunkhwa, Pakistan

    Hepatitis C virus (HCV) is a leading cause of chronic liver disease and frequently progresses towards liver cirrhosis and Hepatocellular Carcinoma (HCC). This study aimed to determine the prevalence of HCV gen...

    Nausheen Nazir, Muhammad Rasul Jan, Amjad Ali, Muhammad Asif, Muhammad Idrees, Mohammad Nisar, Muhammad Zahoor and Naser M. Abd El-Salam

    Virology Journal 2017 14:160

    Published on: 22 August 2017

  8. Research

    New insights into HCV replication in original cells from Aedes mosquitoes

    The existing literature about HCV association with, and replication in mosquitoes is extremely poor. To fill this gap, we performed cellular investigations aimed at exploring (i) the capacity of HCV E1E2 glyco...

    Catherine Fallecker, Alban Caporossi, Yassine Rechoum, Frederic Garzoni, Sylvie Larrat, Olivier François, Pascal Fender, Patrice Morand, Imre Berger, Marie-Anne Petit and Emmanuel Drouet

    Virology Journal 2017 14:161

    Published on: 22 August 2017

  9. Research

    Association of the tandem polymorphisms (rs148314165, rs200820567) in TNFAIP3 with chronic hepatitis B virus infection in Chinese Han population

    Chronic hepatitis B virus (HBV) infection remains an important public health issue. A20, a ubiquitin-editing protein encoded by tumor necrosis factor alpha-inducible protein 3 (TNFAIP3) gene, is complicated in HB...

    Na Li, Ying Shi, Pingping Zhang, Jiao Sang, Fang Li, Huan Deng, Yi Lv, Qunying Han and Zhengwen Liu

    Virology Journal 2017 14:148

    Published on: 7 August 2017

  10. Case report

    Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure

    The major resistance-associated substitution for sofosbuvir (S282T) in HCV NS5B causes severe viral fitness costs and rapidly reverts back to prototype in the absence of selection pressure. Accordingly, resist...

    Andreas Walker, Sandra Filke, Nadine Lübke, Martin Obermeier, Rolf Kaiser, Dieter Häussinger, Jörg Timm and Hans H. Bock

    Virology Journal 2017 14:106

    Published on: 8 June 2017

  11. Research

    Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

    In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-5691484...

    Leen Vijgen, Kim Thys, An Vandebosch, Pieter Van Remoortere, René Verloes and Sandra De Meyer

    Virology Journal 2017 14:101

    Published on: 31 May 2017

  12. Review

    Hepatitis C virus management: potential impact of nanotechnology

    Around 170–200 million individuals have hepatitis C virus (HCV), which represents ~ 3% of the world population, including ~ 3–5 million people in the USA. According to the WHO regional office in the Middle Eas...

    Mostafa H. Elberry, Noureldien H. E. Darwish and Shaker A. Mousa

    Virology Journal 2017 14:88

    Published on: 2 May 2017

Previous Page Page 1 of 6 Next Page